Natural Heart Health Tips
The inflammatory response is an important mechanism for protecting the body from attack by invading organisms and faulty cells. In the case of immune dis-regulation, the body loses its ability to differentiate between innocuous and potentially dangerous substances.
Transform Your Heart is an
educational website and is
an outreach of Fountain of Life.
Serrapeptase vs NSAIDS
Natural Heart Health Product #7
Select whole grains

(Editors note: Obiously this does not apply to those with Gluten Intolerance, or grain allergies.)

Whole grains are good sources of fiber and other nutrients that play a role in regulating blood pressure and heart health. You can increase the amount of whole grains in a heart-healthy diet by making simple substitutions for refined grain products.

Another easy way to add whole grains to your diet is ground flaxseed. Flaxseeds are small brown seeds that are high in fiber and omega-3 fatty acids, which can lower your total blood cholesterol. You can grind the seeds in a coffee grinder or food processor and stir a teaspoon of them into yogurt, applesauce or hot cereal. Grain products to choose Grain products to

From: Mayo Clinic

1) Kee WH. Tan SL, Lee V. Salmon YM. The treatment of breast engorgement with Serrapeptase: a randomised double blind controlled trial. Singapore Med J. 1989:30(1): 48-54.
2) Mizukoshi, D. et al. A double blind clinical study of Serrapeptase in the treatment ofchronic sinusitis. Igaku Ayrni 109:50-62.1979.
3) Carratu, L. et al. Physio-chemical and rheological research on mucolytic activity ofSerrapeptase in chronic broncho-pneumopathies. Curr. Ther. Res. 28(6): 937-951. 1980.
4) Braga, P.C. et al. Effects of Serrapeptase on muco-ciliary clearance in patients with chronic bronchitis. Curr. Ther. Res. 29(5): 738-744,1981.
5) Mazzonie, A. et al. Evaluation of Serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double blind randomised trial versus placebo. J. Int. Med. Res. 18(5): 379-388,1990.
6) Kakinumu, A. et al. Regression of fibrinolysis in scalded rats by administration of Serrapeptase. Biochem. Pharmacol. 31:2861-2866,1982.
7) Marly, M. Enzymotherapie anti-inflammatoire a l’aide de la Serrapeptase: resultats cliniques en traumatologie et en ORL. C RTherapeut. 3:9-19,1985.
8) Odagiri, J. et al. Clinical applications of Serrapeptase in sinusitis. Med. Consult. New Remedy 6:201-209, 1979.
9) Yamazaki, J. et al. Anti-inflammatory activity of Serrapeptase, a protease produced by a strain of Serratia. Folia Pharmacol. Japon. 6^302-314,1967.
10) Harad, Y. Clinical efficacy of Serrapeptase on buccal swelling after radical operation for chronic sinusitis. Igaku Ayumi 123:768-778.1982.
11) Matsudo, A. et at. Effect of Serrapeptase on inflammatory oedema following operation for thyropid disease. Med. Consult. New Remedy 18:171-175, 1981.
12) Fujitani, T. et al. Effect of anti-inflammatory agent on transfer of antibiotics to the maxillary sinus mucosa in chronic sinusitis. Otorhinolaryngol. Clin. North Am. 66:557-565. 1976.
13) Tago. T. and Mitsui, S. Effects of Serrapeptase in dissolution of sputum, especially in patients with bronchial asthma. Jap. Clin. Exp. Med. 49:222-228, 1972.
14) Mazzonie, A. et al. Evaluation of Serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double blind randomised trial versus placebo. J. int. Med. Res. 18(5): 379-388,1990.
15) Kase, Y. et al. A new method for evaluating mucolytic expectorant activity and its application. II. Application to two proteolytic enzymes, Serrapeptase and seaprose. Arzneimittelforschung 32:374-378,1982.
16) Marriott, C. Modification of the rheoloaical properties of mucus by drugs. Adv. Exp. Med. Biol. 144^75-84, 1982.
17) Majima. Y. et al. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am. Rev. Respit. Dis. 141:79-83.1990.
18) Miyata, K. Intestinal absorption of Serrapeptase. J ApplBiochem. 1980:2:111-16.
19) Aso T. et al. Breast engorgement and its treatment: Clinical effects of (Serrapeptase) an anti-inflammatory enzyme preparation. The world of Obstetrics and Gynaecology (Japanese). 1981:33:371-9.
20) Esch PM, Gemgross H. Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joints in treatment with Serrapeptase a prospective study (German). FortschrMed. 1989; 107(4): 67-8, 71-2.
21) Majima Y, lnagaki M, Hirata K. Takeuchi K, M orishita A, Sakakura Y. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol. 1988; 244(6):355-9.
22) Selan L, Berlutti F, Passariello C. Comodi-Ballanti MR, Thaller MC. Proteolytic enzymes: a new treatment strategy for prosthetic infections? Antimicrob Agents Cheroother. 1993; 37(12): 2618-21.
23) Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu H, Hirata M, Arai T, et al. Augmentation by Serrapeptase of tissue permeation by cefotiam (Japanese). Jpn JAntibiot. 1986; 39(3): 761-71.
Our Price
Transform Your Heart is an educational website and is
an outreach of Fountain of Life.
Copyright 2011 Donna Crow
2848 Greentree Way
Eugene, OR 97405 USA
Visit Our Other Sites:
Ear Nose Throat

The use of enzymes with fibrinolytic, proteolytic and anti-edemic activities for the treatment of inflammatory conditions of the ear, nose and throat has gained increasing support in recent years. In a third double-blind study, 193 subjects suffering from acute or chronic ear, nose or throat disorders were evaluated. Treatment with SP lasted 7-8 days, two 5 mg tabs, t.i.d. After 3-4 days treatment, significant symptom regression was observed in the SP-treated group, while this was not noted in the control group. Patients suffering from laryngitis, catarrhal rhinopharyngitis and sinusitis noted markedly rapid improvement. The physicians' assessments of efficacy of treatment were excellent or good for 97.3% of patients treated with SP compared with only 21.9% of those treated with placebo. In a similar study of chronic bronchitis, conducted by a team of otolaryngolosits, the SP-treated group showed excellent results compared with the placebo group in the improvement of loosening sputum, frequency of cough and expectoration. Other improvements included the posterior nasal hydro rhea and rhinos enosis. The administration of SP reduces the viscosity of the nasal mucus to a level at which maximal transport can be achieved. It has also been demonstrated that the simultaneous use of the peptidase and an antibiotic results in increased concentrations of the antibiotic at the site of the infection.

The mechanisms of action of SP, at the sites of various inflammatory processes consist fundamentally of a reduction of the exudative phenomena and an inhibition of the release of the inflammatory mediators. This peptidase induces fragmentation of fibrinose aggregates and reduces the viscosity of exudates, thus facilitating drainage of these products of the inflammatory response and thereby promoting the tissue repair process.

Studies suggest that SP
has a modulatory effect on specific acute phase proteins that are involved in the inflammatory process. This is substantiated by a report of significant reductions in C3 and C4 complement, increases in opsonizing protein and reductions in concentrations of haptoglobulin, which is a scavenger protein that inhibits lysosomal protease.
Carpal Tunnel

Carpal tunnel syndrome is a form of musculol-igamentous strain caused by repetitive motion injury. Individuals who work at keyboard terminals are particularly susceptible to this condition. While surgery has been considered the first line treatment for carpal tunnel syndrome, recent studies reveal that the use of anti-inflammatory enzymes (e.g. SP and bromelain) in conjunction with vitamins B2 and B6 are also effective. The use of
non-invasive, nutritional approaches to the treatment of this common condition will become more important as a generation of keyboard operators approach retirement. Several research groups have reported the intestinal absorption of SP. SP is well absorbed orally when formulated with an enteric coating. It is known that proteases
and peptidases are only absorbed in the intestinal area. These enzymes are mobilized directly to the blood and are not easily detectible in urine. Other enzymes with structural similarities have been reported to be absorbed through the intestinal tract. Chymotrypsin is transported into the blood from the intestinal lumen. Horseradish peroxidase can cross the mucosal barrier of the intestine in a biologically and immunologically active form.

Several studies have appeared so far which refer to the systemic effects of orally given proteases and peptidases (e.g. SP), such as repression of oedema and repression of blood vessel permeability induced by histamine or bradykinin. These enzymes also affect the kallikrein-kinin system and the complement system, thus modifying the inflammatory response. In vitro and in vivo studies reveal that SP has a specific, anti-inflammatory effect, superior to that of other proteolytic enzymes. A review of the scientific literature, including a series of controlled, clinical trials with large patient groups, suggests that Serrapeptase is useful for a broad range of inflammatory

If one considers the fact that anti-inflammatory agents are among the most widely prescribed drugs, the use of a safe, proteolytic enzyme such as SP would be a welcome addition to the physician's armamentarium of physiologic agents.

The simple answer is serrapeptase which is the best anti-inflammatory enzyme available. It does NOT affect any drugs whatsoever except that it may make them unnecessary.
Site Map